GSK plc (GSK)
| Market Cap | 94.19B |
| Revenue (ttm) | 43.24B |
| Net Income (ttm) | 7.39B |
| Shares Out | 3.74B |
| EPS (ttm) | 1.79 |
| PE Ratio | 26.24 |
| Forward PE | 10.40 |
| Dividend | $1.62 (3.46%) |
| Ex-Dividend Date | Aug 15, 2025 |
| Volume | 5,022,815 |
| Open | 46.85 |
| Previous Close | 46.94 |
| Day's Range | 46.57 - 47.12 |
| 52-Week Range | 31.72 - 47.16 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | Oct 29, 2025 |
About GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]
Financial Performance
In 2024, GSK's revenue was 31.38 billion, an increase of 3.46% compared to the previous year's 30.33 billion. Earnings were 2.58 billion, a decrease of -47.75%.
Financial numbers in GBP Financial StatementsNews
GSK plc (GSK) Q3 2025 Earnings Call Transcript
GSK plc ( GSK) Q3 2025 Earnings Call October 29, 2025 8:00 AM EDT Company Participants Emma Walmsley - CEO & Director Luke Miels - Chief Commercial Officer Deborah Waterhouse - CEO of ViiV Healthcare...
GSK Upgrades 2025 Financial Outlook, CEO Says Positioned Well For 2026
British pharmaceutical giant GSK Plc (NYSE:GSK) on Wednesday reported upbeat third-quarter results and upgraded its full-year 2025 guidance.
GSK Raises Guidance After Sales, Earnings Growth
The drugmaker now expects 2025 sales growth between 6% to 7% when excluding currency movements, up from a 3% to 5% range.
GSK raises 2025 sales forecast after strong growth in specialty medicines
GSK raised its 2025 sales expectations on Wednesday after third-quarter results beat expectations, driven by double-digit growth in its specialty medicines, including HIV and oncology.
GSK shares fall as narrow approval of blood cancer drug limits US relaunch
GSK's London-listed shares fell nearly 2% on Friday after the U.S. Food and Drug Administration approved only one of two treatment combinations with the British firm's blood cancer drug, limiting the ...
FTSE 100 Index shares to watch: HSBC, Standard Chartered, Haleon, GSK
The FTSE 100 Index rose for four consecutive days and reached its all-time high of £9,578 as traders reacted to key earnings and macro data. It has jumped by over 27% from its lowest level this year.
Blenrep approved by US FDA for use in treatment of relapsed/refractory multiple myeloma
PHILADELPHIA--(BUSINESS WIRE)-- #BelantamabMafodotin--Blenrep approved by US FDA for use in treatment of relapsed/refractory multiple myeloma.
US FDA approve GSK's blood cancer treatment
The U.S. Food and Drug Administration has approved British drugmaker GSK's blood cancer drug, Blenrep, in combination with other treatments, the company said on Thursday, paving the way for a relaunch...
UK's drug-cost watchdog recommends use of GSK unit's HIV prevention drug
The UK's drugs cost-effectiveness watchdog has given a positive recommendation for ViiV Healthcare's HIV drug, enabling access to the preventive medicine via the state health system in England and Wal...
GSK: Compelling Value, No Red Flags Ahead Of Earnings, Blenrep FDA Decision Soon
GSK plc aka GlaxoSmithKline is rated a Buy at or below $45 due to relative undervaluation and a balanced, diversified portfolio. GSK's recent CEO transition and solid Q2 earnings have improved market ...
GSK's Hidden Growth Engines Beyond HIV And Oncology
GSK continues to successfully develop its oncology franchise. So, sales of its "gem" in the treatment of myelofibrosis, called Ojjaara, reached $183 million in the second quarter of 2025, increasing b...
My Top 5 Biotech Stocks Big Pharma Could Buy Next
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of ...
Focus: US Health Secretary Kennedy speeds autism drug with GSK help
U.S. Health Secretary Robert F Kennedy Jr. could deliver a policy win for the Trump administration in just a few months after the Food and Drug Administration enlisted GSK to help it fast-track approv...
New Local Data in GSK and IQVIA's Vaccine Track Supports Smarter Public Health Action at the Community Level
PHILADELPHIA--(BUSINESS WIRE)-- #AdultVaccination--GSK plc (LSE/NYSE: GSK) today announced a major update to Vaccine Track, a first-of-its-kind, interactive public data tool for tracking adult immuniz...
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Emma Walmsley To Step Down As GSK CEO After Nine Years, Luke Miels To Lead Starting January 2026
GSK plc (NYSE: GSK) appointed Luke Miels as the CEO Designate of GSK. He will assume full responsibility as CEO and join the Board on January 1, 2026.
GSK turns to insider to be next CEO — and the stock rallies
Shares of U.K. pharmaceutical giant GSK rallied on Monday after it turned to an insider to become its next CEO.
Who is GSK's next CEO Luke Miels?
British drugmaker GSK named insider Luke Miels as its CEO designate on Monday to succeed Emma Walmsley, who will step down after nine years in the role.
GSK names Luke Miels as next CEO after Emma Walmsley steps down; shares jump
GSK announced on Monday that Chief Executive Emma Walmsley will step down after nine years in the role, with current Chief Commercial Officer Luke Miels set to take over on January 1. The transition m...
GSK names Luke Miels as CEO designate
British drugmaker GSK said on Monday it has appointed Luke Miels as CEO designate and he will assume full responsibilities as chief executive on January 1, 2026.
GSK plc (GSK) plc Presents at Bank of America Global Healthcare Conference 2025 Transcript
GSK plc (NYSE:GSK) plc Bank of America Global Healthcare Conference 2025 September 24, 2025 4:00 AM EDT Company Participants Julie Brown - CFO & Executive Director Tony Wood - Chief Scientific Office...
Pi Health to Collaborate with GSK to Enhance Clinical Research Services
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Pi Health, a global health technology and clinical research company, today announced it will provide fully outsourced clinical research services in a GSK clinical tr...
GSK to submit label update for Leucovorin at FDA's request, does not intend to market it for autism
CNBC's Angelica Peebles joins 'Fast Money' with breaking news on GSK and its drug Leucovorin.
FDA approves drug that Trump due to suggest as autism treatment
The U.S. Food and Drug Administration announced approval of leucovorin, a form of folic acid that U.S. President Donald Trump was slated to suggest as a treatment for autism symptoms at a White House ...
UK's GSK announces $30 billion U.S. pharma investment amid Trump state visit
British pharmaceutical giant GSK committed to investing at least $30 billion in U.S. research and developing and manufacturing over the next five years.